Stock A068270 CELLTRION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
176,200 KRW -0.62% Intraday chart for Celltrion, Inc. -2.06% -12.56%
May. 24 Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe CI
May. 10 Celltrion's Q1 Attributable Profit Slumps 86% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 24,175,552 48,989,351 27,592,583 23,000,359 27,970,378 36,260,905 - -
Enterprise Value (EV) 2 24,047 49,090 27,117 23,236 29,280 36,982 36,155 35,210
P/E ratio 77.7 x 94.4 x 47.2 x 41.6 x 53.7 x 69.5 x 33.9 x 23.1 x
Yield - - 0.38% - 0.25% 0.25% 0.27% 0.32%
Capitalization / Revenue 21.4 x 26.5 x 14.6 x 10.1 x 12.9 x 10.4 x 8.73 x 7.37 x
EV / Revenue 21.3 x 26.5 x 14.3 x 10.2 x 13.5 x 10.6 x 8.7 x 7.16 x
EV / EBITDA 44.8 x 55.1 x 27.9 x 26.6 x 32.6 x 38.9 x 22.3 x 15.6 x
EV / FCF 63.3 x 186 x 46 x -211 x 89.5 x 71.7 x 38.9 x 31.4 x
FCF Yield 1.58% 0.54% 2.17% -0.47% 1.12% 1.39% 2.57% 3.18%
Price to Book 8.27 x 14.4 x 6.87 x 5.34 x 2.46 x 2.17 x 2.05 x 1.9 x
Nbr of stocks (in thousands) 144,521 144,757 144,931 143,304 138,811 205,794 - -
Reference price 3 167,280 338,424 190,385 160,500 201,500 176,200 176,200 176,200
Announcement Date 2/19/20 2/22/21 2/16/22 3/3/23 2/29/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,128 1,849 1,891 2,284 2,176 3,485 4,155 4,920
EBITDA 1 537.3 891.4 972.1 873.6 897.2 950 1,624 2,262
EBIT 1 378.1 712.1 753.9 647.2 651.5 692.1 1,490 2,102
Operating Margin 33.5% 38.51% 39.87% 28.34% 29.93% 19.86% 35.86% 42.73%
Earnings before Tax (EBT) 1 378.6 650.7 746.9 626.2 671.1 689.7 1,472 1,991
Net income 1 297.6 511.3 575.1 533.2 535.6 540.3 1,100 1,553
Net margin 26.37% 27.65% 30.42% 23.34% 24.61% 15.5% 26.47% 31.56%
EPS 2 2,153 3,586 4,031 3,855 3,753 2,534 5,205 7,638
Free Cash Flow 3 379,716 263,739 589,594 -110,305 327,112 515,600 930,000 1,121,000
FCF margin 33,649.04% 14,262.95% 31,181.9% -4,829.54% 15,029.76% 14,793.42% 22,380.28% 22,786.11%
FCF Conversion (EBITDA) 70,673.9% 29,586.45% 60,648.72% - 36,460.8% 54,273.79% 57,282.34% 49,561.95%
FCF Conversion (Net income) 127,593.57% 51,582.76% 102,521.45% - 61,068.54% 95,428.47% 84,553.14% 72,200.31%
Dividend per Share 2 - - 721.2 - 500.0 444.0 476.8 555.8
Announcement Date 2/19/20 2/22/21 2/16/22 3/3/23 2/29/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 601.1 550.6 596.1 645.6 510.6 597.5 524 672.3 382.6 737 792.7 921.3 1,050 975.3 1,063
EBITDA 1 - - - - - - - - - 147 200 - - 445 489
EBIT 1 219 142.3 199 213.8 100.6 182.4 183 267.6 18.42 15.44 94.57 231.8 341.2 320.8 374.4
Operating Margin 36.43% 25.84% 33.38% 33.11% 19.71% 30.52% 34.92% 39.81% 4.82% 2.09% 11.93% 25.15% 32.51% 32.89% 35.21%
Earnings before Tax (EBT) 145.2 - 226.8 217.3 48.49 208.2 189.7 282.9 - - - - - - -
Net income 1 120.5 118.5 183.4 166.7 64.53 166.9 147.5 221.8 1.054 22.44 63 173 202 296 331
Net margin 20.04% 21.53% 30.77% 25.82% 12.64% 27.93% 28.15% 33% 0.28% 3.04% 7.95% 18.78% 19.25% 30.35% 31.13%
EPS 2 - - - 1,162 470.0 1,155 1,034 1,561 - - 494.3 954.4 1,330 - -
Dividend per Share 2 - - - - - - - - 500.0 - - - 200.0 - -
Announcement Date 2/16/22 5/12/22 8/5/22 11/9/22 3/3/23 5/8/23 8/14/23 11/7/23 2/29/24 5/9/24 - - - - -
1KRW in Billions2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 100 - 236 1,310 721 - -
Net Cash position 1 128 - 476 - - - 106 1,051
Leverage (Debt/EBITDA) - 0.1126 x - 0.2696 x 1.46 x 0.7589 x - -
Free Cash Flow 2 379,716 263,739 589,594 -110,305 327,112 515,600 930,000 1,121,000
ROE (net income / shareholders' equity) 11.2% 16.7% 16.5% 12.9% 5.07% 3.13% 6.83% 8.41%
ROA (Net income/ Total Assets) 8.02% 11.6% 10.7% 9.22% 4.31% 2.89% 5.51% 7.03%
Assets 1 3,713 4,402 5,372 5,783 12,421 18,723 19,946 22,075
Book Value Per Share 3 20,218 23,501 27,732 30,040 81,950 81,220 85,903 92,564
Cash Flow per Share 3 3,430 2,460 6,417 6.250 3,764 3,945 7,788 10,103
Capex 1 94.3 87 63.4 111 210 107 152 152
Capex / Sales 8.35% 4.71% 3.35% 4.87% 9.65% 3.06% 3.67% 3.1%
Announcement Date 2/19/20 2/22/21 2/16/22 3/3/23 2/29/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Celltrion, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
176,200 KRW
Average target price
231,882 KRW
Spread / Average Target
+31.60%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. Financials Celltrion, Inc.